Without severe side effects, IMMU-132 has been effective against triple-negative breast cancer [19], metastatic small cell lung carcinoma (SCLC) [14], and metastatic non-SCLC (NSCLC) resistant to anti-PD-1/PD-L1 therapy [15]. This evidence concerns the gene CD274 and small cell lung carcinoma.